Related Experiment Video
Updated: Jul 4, 2026
08:40
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
A rapid ELISA-based serum assay for myelin basic protein in multiple sclerosis
A J Chamczuk1, M Ursell, P O'Connor
1Structural Biology and Biochemistry, Research Institute, The Hospital For Sick Children, Toronto, ON, Canada M5G 1X8.
Journal of Immunological Methods
|May 2, 2002
Summary
A new ELISA assay detects autoantibodies to myelin basic protein (MBP) in multiple sclerosis (MS) patients. This sensitive test identifies 77% of MS cases, offering a potential diagnostic tool for this neurological disease.
Area of Science:
- Neuroimmunology
- Biochemistry
Background:
- Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
- Autoantibodies against myelin basic protein (MBP) are implicated in MS pathogenesis.
Purpose of the Study:
- To develop and validate a sensitive enzyme-linked immunosorbent assay (ELISA) for detecting autoantibodies to MBP in human serum.
- To assess the diagnostic potential of MBP autoantibodies in differentiating MS patients from healthy individuals.
Main Methods:
- Development of an ELISA assay utilizing heparin to neutralize the positive charge of MBP.
- Measurement of MBP autoantibody (IgG) levels in serum samples from 94 clinically definite MS patients and 98 healthy adults.
- Receiver-operator curve (ROC) analysis to determine assay sensitivity and specificity.
Main Results:
- The assay detected elevated MBP autoantibodies in 77% of MS patients, compared to only 5% of healthy controls.
- The established clinical decision limit demonstrated high sensitivity (77%) and specificity (95%).
- Assay performance was unaffected by common serum interferents like hemoglobin, triglycerides, and bilirubin.
Conclusions:
- The developed ELISA assay is a sensitive and specific tool for detecting MBP autoantibodies.
- Elevated MBP autoantibody levels show significant diagnostic potential for multiple sclerosis.
- This assay could aid in the diagnosis and understanding of MS immunopathology.
Related Concept Videos
01:33Enzyme-Linked Immunosorbent Assay
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...